UBS Remains a Hold on Cytokinetics (CYTK)
UBS analyst Ashwani Verma reiterated a Hold rating on Cytokinetics today and set a price target of $69.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Verma covers the Healthcare sector, focusing on stocks such as United Therapeutics, Axsome Therapeutics, and Teva Pharmaceutical. According to TipRanks, Verma has an average return of 9.5% and a 49.61% success rate on recommended stocks.
In addition to UBS, Cytokinetics also received a Hold from TipRanks – PerPlexity’s PerPlexity Biotechnology in a report issued on February 27. However, yesterday, RBC Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK).
Based on Cytokinetics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.76 million and a GAAP net loss of $183.03 million. In comparison, last year the company earned a revenue of $16.93 million and had a GAAP net loss of $150.02 million
Based on the recent corporate insider activity of 156 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year. Earlier this month, Andrew Callos, the EVP & CCO of CYTK sold 26,000.00 shares for a total of $1,608,730.00.
Read More on CYTK:
Disclaimer & DisclosureReport an Issue
- Cytokinetics Earnings Call Marks High-Stakes Launch Phase
- FDA Disruptions and Budget Cuts Pose Rising Regulatory Risk to Cytokinetics’ Drug Pipeline
- Cytokinetics management to meet with B. Riley
- Cytokinetics price target raised to $67 from $66 at BofA
- Cytokinetics price target raised to $98 from $95 at Stifel
